Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of Alzheimer’s Disease

Study Presented at CNS Summit 2013 Suggests ANAVEX 2-73 Will Have Clinically Detectable and Meaningful Effect in Alzheimer’s Disease, Especially When Combined With Aricept® New York, NY — November 18, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) presented new data from a study evaluating ANAVEX 2-73 in a computer simulation…

Anavex Announces Positive Data for ANAVEX 2-73 in Alzheimer’s Disease

Data Presented at Society for Neuroscience 2013 Annual Meeting New York, NY — November 12, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) is pleased to announce that new study data showed ANAVEX 2-73 to be effective in counteracting the progression of Alzheimer’s disease under chronic treatment in a transgenic mouse model…

Anavex CEO to Present Clinical Prediction Data for ANAVEX 2-73 at CNS Summit 2013

New York, NY — November 7, 2013 — Anavex Life Sciences Corp. (OTCQB: AVXL) is pleased to announce that its President and Chief Executive Officer Christopher U. Missling, PhD, will be presenting new clinical predication data supporting its investigational compound, ANAVEX 2-73, as a potential therapeutic for the treatment of Alzheimer’s disease.  The data will…

Anavex Reports ANAVEX 2-73 Blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of Alzheimer’s Disease

New York, NY — November 4, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) announces that issue 38 (2013) of the international scientific journal Neuropsychopharmacology contains a report demonstrating that ANAVEX 2-73 dose-dependently blocks Tau and amyloid-beta (“amyloid”) proteins and memory deficit in a mouse model of Alzheimer’s disease (AD). A reduction in…

Anavex to Present Data for ANAVEX 2-73 at Society for Neuroscience 2013 Annual Meeting

New York, NY — October 29, 2013 — Anavex Life Sciences Corp. (OTCQB: AVXL) today announced that Tangui Maurice, PhD, CNRS Research Director, Head of Team 2 ‘Endogenous Neuroprotection in Neurodegenerative Diseases’, at the University of Montpellier and INSERM, will be presenting new data supporting the investigational compound ANAVEX 2-73 as a potential therapeutic for…

Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73 for Alzheimer’s Disease

New York, NY — October 22, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that the current issue of the peer-reviewed scientific journal PLOS ONE explains that sigma-1 receptor (Sig-1R) activity is involved in cellular survival by regulating and stabilizing a key cell stress sensor.  These findings may explain…

Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York

New York, NY — September 3, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013 at 3:15 p.m. ET in Room 7.03 of the…